Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Fox Chase Chemical Diversity Center, Inc., Pennsylvania Biotechnology Center, Doylestown, PA 18902, USA.
Viruses. 2022 Sep 13;14(9):2025. doi: 10.3390/v14092025.
While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.
虽然抗逆转录病毒药物改变了 HIV 感染者的生活,但为了防止病毒储存细胞反弹,需要进行慢性治疗。HIV 感染者还面临更高的心血管和神经认知并发症以及癌症风险。因此,寻找治愈 HIV-1 感染是当前艾滋病研究的一个重要目标。这篇综述集中讨论了 HIV-1 Nef 辅助蛋白药理学抑制剂的发现。众所周知,Nef 可增强 HIV-1 的感染力和复制能力,并通过阻止 HIV-1 抗原在细胞表面 MHC-I 的表达来促进 HIV 感染细胞的免疫逃逸。最近的进展表明,Nef 抑制剂不仅能抑制 HIV-1 的复制,还能使足够的 MHC-I 恢复到受感染细胞的表面,从而引发细胞毒性 T 淋巴细胞反应。将 Nef 抑制剂与潜伏期逆转剂和治疗性疫苗相结合,可能为清除病毒储存库提供一条途径。